Pierre-Louis Toutain

List of Publications by Year
in descending order

277	9,084	47006 47	62596 80
papers	citations	h-index	g-index

286	286	286	6787
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations. Equine Veterinary Journal, 2022, 54, 979-988.	1.7	6
2	Pharmacology, safety, efficacy and clinical uses of the COXâ€2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 2022, 45, 325-351.	1.3	11
3	Determination of the pharmacokineticâ€pharmacodynamic cutâ€off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing. Equine Veterinary Journal, 2021, 53, 1047-1055.	1.7	2
4	A history of antimicrobial drugs in animals: Evolution and revolution. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 137-171.	1.3	39
5	The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 172-200.	1.3	42
6	Validating an empiric sulfadiazineâ€“trimethoprim dosage regimen for treatment of Escherichia coli and Staphylococcus delphini infections in mink (Neovison vison). Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 93-106.	1.3	6
7	Dynamic interactions between cephalexin and macrophages on different Staphylococcus aureus inoculum sizes: a tripartite in vitro model. BMC Veterinary Research, 2021, 17, 23.	1.9	2
8	Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses. Equine Veterinary Journal, 2021, 53, 1239-1249.	1.7	6
9	Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach. Veterinary Research, 2021, 52, 34.	3.0	4
10	Towards a Better and Harmonized Education in Antimicrobial Stewardship in European Veterinary Curricula. Antibiotics, 2021, 10, 364.	3.7	15
11	Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. BMC Veterinary Research, 2021, 17, 149.	1.9	9
12	A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients. Frontiers in Pharmacology, 2021, 12, 666348.	3.5	2
13	A new LC/MS method for specific determination of human systemic exposure to bisphenol A, F and S through their metabolites: Application to cord blood samples. Environment International, 2021, 151, 106429.	10.0	14
14	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. Journal of Veterinary Pharmacology and Therapeutics, 2021, 44, 733-744.	1.3	3
15	What Matters in Pigletsâ€™ Exposure to Antibiotics Administered through Drinking Water?. Antibiotics, 2021, 10, 1067.	3.7	2
16	Use of Mixture Dosing and Nonlinear Mixed Effect Modeling of Eight Environmental Contaminants in Rabbits to Improve Extrapolation Value of Toxicokinetic Data. Environmental Health Perspectives, 2021, 129, 117006.	6.0	1
17	Population Pharmacokinetics of Intravenous Amoxicillin Combined With Clavulanic Acid in Healthy and Critically Ill Dogs. Frontiers in Veterinary Science, 2021, 8, 770202.	2.2	2
18	The Decline and Fall of Materia Medica and the Rise of Pharmacology and Therapeutics in Veterinary Medicine. Frontiers in Veterinary Science, 2021, 8, 777809.	2.2	2

#	Article	IF	Citations
19	Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?. Clinical Pharmacokinetics, 2020, 59, 1-5.	3.5	12
20	Re: â€œEvaluation of Enrofloxacin for Use in Cryopreservation of Zebu Bull (Bos indicus) Semenâ€• by Ishaq et al. (Biopreserv Biobank 2019;17(6):546â€“552, DOI: 10.1089/bio.2018.0133). Biopreservation and Biobanking, 2020, 18, 41-42.	1.0	1
21	Authorsâ€™ Reply to Yu et al.: â€œLevothyroxÂ® New and Old Formulations: Are They Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2020, 59, 283-285.	3.5	1
22	Authorsâ€™ Reply to Krebs-Brown et al. Comment on: â€œWhy Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?â€• Clinical Pharmacokinetics, 2020, 59, 269-271.	3.5	0
23	Authorsâ€™ Reply to Nicolas: â€œWhy Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?â€• Clinical Pharmacokinetics, 2020, 59, 277-279.	3.5	0
24	Toxicokinetics of bisphenol S in rats for predicting human bisphenol S clearance from allometric scaling. Toxicology and Applied Pharmacology, 2020, 386, 114845.	2.8	16
25	A New Drugâ€“Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. Drug Safety, 2020, 43, 657-660.	3.2	10
26	Toxicokinetics of bisphenol-S and its glucuronide in plasma and urine following oral and dermal exposure in volunteers for the interpretation of biomonitoring data. Environment International, 2020, 138, 105644.	10.0	44
27	Oral Systemic Bioavailability of Bisphenol A and Bisphenol S in Pigs. Environmental Health Perspectives, 2019, 127, 77005.	6.0	60
28	VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle. Frontiers in Microbiology, 2019, 10, 1310.	3.5	28
29	Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens. Frontiers in Microbiology, 2019, 10, 1237.	3.5	12
30	Authorsâ€™ Reply to Lechat et al.: â€œLevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2019, 58, 1353-1354.	3.5	6
31	Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus. PLoS ONE, 2019, 14, e0211214.	2.5	13
32	Authorâ€™s Reply to Trechot: â€œComment on LevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2019, 58, 979-980.	3.5	0
33	Authorsâ€™ Reply to Castello-Bridoux et al.: â€œComment on LevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2019, 58, 973-975.	3.5	2
34	Authorsâ€™ Reply to Coste et al.: â€œLevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2019, 58, 967-968.	3.5	2
35	Authorsâ€™ Reply to Nicolas: â€œLevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?â€• Clinical Pharmacokinetics, 2019, 58, 961-963.	3.5	0
36	Comment on â€œToxicokinetics of bisphenol A, bisphenol S, and bisphenol F in a pregnancy sheep modelâ€• Chemosphere, 2019, 227, 703-704.	8.2	2

#	Article	IF	Citations
37	LevothyroxÂ® New and Old Formulations: Are they Switchable for Millions of Patients?. Clinical Pharmacokinetics, 2019, 58, 827-833.	3.5	34
38	Is bisphenol S a safer alternative to bisphenol A in terms of potential fetal exposure ? Placental transfer across the perfused human placenta. Chemosphere, 2019, 221, 471-478.	8.2	30
39	Evaluation and validation of an analytical approach for high-throughput metabolomic fingerprinting using direct introductionâ€“high-resolution mass spectrometry: Applicability to classification of urine of scrapie-infected ewes. European Journal of Mass Spectrometry, 2019, 25, 251-258.	1.0	8
40	Scabies in an obese patient: How should the ivermectin dosing be adapted?. MÃ©decine Et Maladies Infectieuses, 2019, 49, 286-288.	5.0	1
41	Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 52-59.	1.3	9
42	Comment on â€˜Pharmacokinetics of bisphenol S in humans after a single oral administrationâ€™. Environment International, 2018, 116, 29.	10.0	2
43	Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods. Clinica Chimica Acta, 2018, 479, 56-65.	1.1	13
44	Mixing of Shiga toxin-producing and enteropathogenic Escherichia coli in a wastewater treatment plant receiving city and slaughterhouse wastewater. International Journal of Hygiene and Environmental Health, 2018, 221, 355-363.	4.3	9
45	Mathematical modeling and simulation in animal health. Part <scp>III</scp>: Using nonlinear mixedâ€effects to characterize and quantify variability in drug pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 171-183.	1.3	67
46	Pharmacokinetics of tiludronate in horses: A field population study. Equine Veterinary Journal, 2018, 50, 488-492.	1.7	8
47	Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. Frontiers in Pharmacology, 2018, 9, 1137.	3.5	9
48	Bisphenol S instead of Bisphenol A: Toxicokinetic investigations in the ovine materno-feto-placental unit. Environment International, 2018, 120, 584-592.	10.0	37
49	Optimization of Antimicrobial Treatment to Minimize Resistance Selection. , 2018, , 637-673.		4
50	Optimization of Antimicrobial Treatment to Minimize Resistance Selection. Microbiology Spectrum, 2018, 6, .	3.0	42
51	Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model. Frontiers in Microbiology, 2018, 9, 572.	3.5	22
52	Pharmacokineticâ€“pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 28-38.	1.3	20
53	Diagnostic microbiology in veterinary dermatology: present and future. Veterinary Dermatology, 2017, 28, 146.	1.2	28
54	Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations. Foodborne Pathogens and Disease, 2017, 14, 152-159.	1.8	10

#	Article	IF	Citations
55	A large potentiation effect of serum on the inÂvitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 419-428.	1.3	17
56	Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?. Journal of Antimicrobial Chemotherapy, 2017, 72, 2407-2409.	3.0	9
57	Sulfadimethoxine in giant freshwater prawns (Macrobrachium rosenbergii): an attempt to estimate the withdrawal time by a population pharmacokinetic approach. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 476-485.	1.3	4
58	The authors of â€˜Comparison of veterinary drugs and veterinary homeopathy: part 1 and 2â€™, respond. Veterinary Record, 2017, 181, 457-458.	0.3	1
59	Development of an on-line solid phase extraction ultra-high-performance liquid chromatography technique coupled to tandem mass spectrometry for quantification of bisphenol S and bisphenol S glucuronide: Applicability to toxicokinetic investigations. Journal of Chromatography A, 2017, 1526, 39-46.	3.7	23
60	Comparison of veterinary drugs and veterinary homeopathy: part 2. Veterinary Record, 2017, 181, 198-207.	0.3	11
61	Comparison of veterinary drugs and veterinary homeopathy: part 1. Veterinary Record, 2017, 181, 170-176.	0.3	13
62	Prediction of human prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-physiological toxicokinetic model. Scientific Reports, 2017, 7, 15330.	3.3	16
63	Standard <scp>PK</scp>/<scp>PD</scp> concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 16-27.	1.3	47
64	Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. Drug Testing and Analysis, 2017, 9, 1372-1384.	2.6	9
65	Implementing Precision Antimicrobial Therapy for the Treatment of Bovine Respiratory Disease: Current Limitations and Perspectives. Frontiers in Veterinary Science, 2017, 4, 143.	2.2	7
66	En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach. Frontiers in Microbiology, 2017, 8, 2344.	3.5	122
67	Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice. PLoS ONE, 2017, 12, e0182863.	2.5	13
68	Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms. Frontiers in Microbiology, 2016, 7, 1187.	3.5	9
69	Veterinary Medicine Needs New Green Antimicrobial Drugs. Frontiers in Microbiology, 2016, 7, 1196.	3.5	56
70	In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations. Frontiers in Microbiology, 2016, 7, 2051.	3.5	25
71	Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida. Veterinary Journal, 2016, 218, 60-64.	1.7	5
72	Characterization of the contribution of buccal absorption to internal exposure to bisphenol A through the diet. Food and Chemical Toxicology, 2016, 93, 82-88.	3.6	13

#	Article	IF	Citations
73	Dominant plasmids carrying extendedâ€spectrum Î²â€lactamases bla_{CTXâ€M} genes in genetically diverse Escherichia coli from slaughterhouse and urban wastewaters. Environmental Microbiology Reports, 2016, 8, 789-797.	2.4	6
74	Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A. Environment International, 2016, 86, 52-59.	10.0	49
75	Comment on â€œ In Vitro Effects of Bisphenol A Î²-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytesâ€. Environmental Health Perspectives, 2015, 123, A289.	6.0	3
76	Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies. PLoS ONE, 2015, 10, e0141441.	2.5	8
77	Conjugation and Deconjugation Reactions within the Fetoplacental Compartment in a Sheep Model: A Key Factor Determining Bisphenol A Fetal Exposure. Drug Metabolism and Disposition, 2015, 43, 467-476.	3.3	44
78	Oral Communications. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 1-81.	1.3	1
79	Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 457-470.	1.3	32
80	Allometric scaling for predicting human clearance of bisphenol A. Toxicology and Applied Pharmacology, 2015, 284, 323-329.	2.8	19
81	Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 1-14.	1.3	19
82	Holding Thermal Receipt Paper and Eating Food after Using Hand Sanitizer Results in High Serum Bioactive and Urine Total Levels of Bisphenol A (BPA). PLoS ONE, 2014, 9, e110509.	2.5	163
83	Rebuttal to the reaction of the <scp>EGGVP</scp> to the review article â€˜The consequences of generic marketing on antibiotic consumption and the spread of microbial resistance: the need for new antibioticsâ€™. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 618-623.	1.3	2
84	Bidirectional placental transfer of Bisphenol A and its main metabolite, Bisphenol A-Glucuronide, in the isolated perfused human placenta. Reproductive Toxicology, 2014, 47, 51-58.	2.9	54
85	Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 354-366.	1.3	19
86	Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure Klebsiella pneumoniae Lung Infections but Differentially Impact the Levels of Antibiotic Resistance in Fecal Flora. Antimicrobial Agents and Chemotherapy, 2014, 58, 1744-1748.	3.2	37
87	Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs. American Journal of Veterinary Research, 2014, 75, 124-131.	0.6	28
88	Exposure variability of fosfomycin administered to pigs in food or water: Impact of social rank. Research in Veterinary Science, 2014, 96, 153-159.	1.9	28
89	Workshop report: The 2012 Antimicrobial Agents in Veterinary Medicine: exploring the consequences of antimicrobial drug use: a 3<scp>â€D</scp> approach. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, e1-e16.	1.3	12
90	Comparison of the reduction in the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-determining region or by the inoculum size effect. International Journal of Antimicrobial Agents, 2014, 44, 472-474.	2.5	4

#	Article	IF	Citations
91	Should oral gavage be abandoned in toxicity testing of endocrine disruptors?. Environmental Health, 2014, 13, 46.	4.0	114
92	Bisphenol A (BPA) pharmacokinetics with daily oral bolus or continuous exposure via silastic capsules in pregnant rhesus monkeys: Relevance for human exposures. Reproductive Toxicology, 2014, 45, 105-116.	2.9	53
93	The consequences of generic marketing on antibiotic consumption and the spread of microbial resistance: the need for new antibiotics. Journal of Veterinary Pharmacology and Therapeutics, 2013, 36, 420-424.	1.3	17
94	Maternal and Fetal Exposure to Bisphenol A Is Associated with Alterations of Thyroid Function in Pregnant Ewes and Their Newborn Lambs. Endocrinology, 2013, 154, 521-528.	2.8	31
95	Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog. BMC Veterinary Research, 2013, 9, 250.	1.9	14
96	Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: Comparison of bactericidal activity at the gut versus the systemic level in a pig model. International Journal of Antimicrobial Agents, 2013, 42, 429-435.	2.5	24
97	Persistence and prevalence of pathogenic and extended-spectrum beta-lactamase-producing Escherichia coli in municipal wastewater treatment plant receiving slaughterhouse wastewater. Water Research, 2013, 47, 4719-4729.	11.3	45
98	Control of medication in horses: Detection time, withdrawal time and beyond. Veterinary Journal, 2013, 198, 305-306.	1.7	1
99	Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses. Veterinary Journal, 2013, 196, 294-303.	1.7	51
100	Bisphenol A Disposition in the Sheep Maternal-Placental-Fetal Unit: Mechanisms Determining Fetal Internal Exposure1. Biology of Reproduction, 2013, 89, 11.	2.7	40
101	High Bioavailability of Bisphenol A from Sublingual Exposure. Environmental Health Perspectives, 2013, 121, 951-956.	6.0	83
102	Phenylbutazone in horses and man: Properties relevant to safety of humans consuming horse meat containing phenylbutazone and its metabolites. Equine Veterinary Education, 2013, 25, 545-549.	0.6	4
103	Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 2013, 36, 417-419.	1.3	13
104	Veterinary pharmacology: history, current status and future prospects. Journal of Veterinary Pharmacology and Therapeutics, 2013, 36, 105-115.	1.3	4
105	Florfenicol concentrations in ovine tear fluid following intramuscular and subcutaneous administration and comparison with the minimum inhibitory concentrations against mycoplasmal strains potentially involved in infectious keratoconjunctivitis. American Journal of Veterinary Research, 2013, 74, 268-274.	0.6	9
106	Interpreting Bisphenol A Absorption in the Canine Oral Cavity: Gayrard et al. Respond. Environmental Health Perspectives, 2013, 121, A323-4.	6.0	8
107	The role of pharmacokinetics in veterinary drug residues. Drug Testing and Analysis, 2012, 4, 34-39.	2.6	10
108	Bisphenol A in Thermal Paper Receipts: Taylor et al. Respond. Environmental Health Perspectives, 2012, 120, .	6.0	0

#	Article	IF	Citations
109	Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation. Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 19-32.	1.3	27
110	Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination. Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 17-29.	1.3	18
111	Establishing bioequivalence of veterinary premixes (Type A medicated articles). Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 53-63.	1.3	5
112	Should licking behavior be considered in the bioavailability evaluation of transdermal products?. Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 39-43.	1.3	31
113	Challenges obtaining a biowaiver for topical veterinary dosage forms. Journal of Veterinary Pharmacology and Therapeutics, 2012, 35, 103-114.	1.3	8
114	Simultaneous quantification of bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: Applicability to toxicokinetic investigations. Talanta, 2011, 85, 2053-2059.	5.5	53
115	Licking behaviour induces partial anthelmintic efficacy of ivermectin pour-on formulation in untreated cattle. International Journal for Parasitology, 2011, 41, 563-569.	3.1	29
116	Ketoprofen in piglets: enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 338-349.	1.3	38
117	Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 376-387.	1.3	30
118	Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Veterinary Microbiology, 2011, 148, 292-297.	1.9	44
119	Competitive binding to plasma thyroid hormone transport proteins and thyroid disruption by phenylbutazone used as a probe. General and Comparative Endocrinology, 2011, 174, 225-231.	1.8	5
120	Generation and processing of urinary and plasmatic metabolomic fingerprints to reveal an illegal administration of recombinant equine growth hormone from LC-HRMS measurements. Metabolomics, 2011, 7, 84-93.	3.0	39
121	Clinical, electroretinographic and histomorphometric evaluation of the retina in sheep with natural scrapie. BMC Veterinary Research, 2011, 7, 25.	1.9	12
122	Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy, 2011, 66, 1798-1809.	3.0	44
123	Paw Inflammation Model in Dogs for Preclinical Pharmacokinetic/Pharmacodynamic Investigations of Nonsteroidal Anti-Inflammatory Drugs. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 548-558.	2.5	27
124	Comparison of Serum Bisphenol A Concentrations in Mice Exposed to Bisphenol A through the Diet versus Oral Bolus Exposure. Environmental Health Perspectives, 2011, 119, 1260-1265.	6.0	83
125	Similarity of Bisphenol A Pharmacokinetics in Rhesus Monkeys and Mice: Relevance for Human Exposure. Environmental Health Perspectives, 2011, 119, 422-430.	6.0	242
126	Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse. Equine Veterinary Journal, 2010, 34, 242-249.	1.7	60

#	Article	IF	Citations
127	Pharmacokinetics of marbofloxacin in horses. Equine Veterinary Journal, 2010, 34, 366-372.	1.7	47
128	Hyaluronan in horses: physiological production rate, plasma and synovial fluid concentrations in control conditions and following sodium hyaluronate administration. Equine Veterinary Journal, 2010, 36, 482-487.	1.7	16
129	Quantification of fipronil and its metabolite fipronil sulfone in rat plasma over a wide range of concentrations by LC/UV/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1934-1938.	2.3	42
130	Estrogenicity of Bisphenol A: A Concentration-Effect Relationship on Luteinizing Hormone Secretion in a Sensitive Model of Prepubertal Lamb. Toxicological Sciences, 2010, 117, 54-62.	3.1	23
131	Emergence of Resistant Klebsiella pneumoniae in the Intestinal Tract during Successful Treatment of Klebsiella pneumoniae Lung Infection in Rats. Antimicrobial Agents and Chemotherapy, 2010, 54, 2960-2964.	3.2	21
132	Is the mechanisms of fipronil-induced thyroid disruption specific of the rat: Re-evaluation of fipronil thyroid toxicity in sheep?. Toxicology Letters, 2010, 194, 51-57.	0.8	27
133	Veterinary Medicines and Competition Animals: The Question of Medication Versus Doping Control. Handbook of Experimental Pharmacology, 2010, , 315-339.	1.8	27
134	How to extrapolate a withdrawal time from an EHSLC published detection time: A Monte Carlo simulation appraisal. Equine Veterinary Journal, 2010, 42, 248-254.	1.7	24
135	Effect of an enduranceâ€like exercise on the disposition and detection time of phenylbutazone and dexamethasone in the horse: Application to medication control. Equine Veterinary Journal, 2010, 42, 240-247.	1.7	15
136	Species Differences in Pharmacokinetics and Pharmacodynamics. Handbook of Experimental Pharmacology, 2010, , 19-48.	1.8	182
137	Pharmacokinetic/Pharmacodynamic Analysis of the Influence of Inoculum Size on the Selection of Resistance in Escherichia coli by a Quinolone in a Mouse Thigh Bacterial Infection Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 3384-3390.	3.2	42
138	Relatedness of Escherichia coli Strains with Different Susceptibility Phenotypes Isolated from Swine Feces during Ampicillin Treatment. Applied and Environmental Microbiology, 2009, 75, 2999-3006.	3.1	32
139	Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 4740-4748.	3.2	41
140	New antibiotics in orphan food-producing animals: What is the responsibility of a Journal regarding good veterinary practice?. Veterinary Journal, 2009, 179, 155-157.	1.7	0
141	Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenaseâ€2. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 1-17.	1.3	59
142	Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COXâ€2 selective drug robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 18-30.	1.3	47
143	Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 31-40.	1.3	47
144	Fipronil-induced disruption of thyroid function in rats is mediated by increased total and free thyroxine clearances concomitantly to increased activity of hepatic enzymes. Toxicology, 2009, 255, 38-44.	4.2	91

#	Article	IF	Citations
145	Increased GH secretion in scrapie, a prion-associated neurodegenerative disease, is not due to suppressed IGF-1 negative feedback. Domestic Animal Endocrinology, 2009, 36, 127-137.	1.6	2
146	Blood clearance of the prion protein introduced by intravenous route in sheep is influenced by host genetic and physiopathologic factors. Transfusion, 2008, 48, 609-619.	1.6	1
147	Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis. American Journal of Veterinary Research, 2008, 69, 410-415.	0.6	14
148	Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine. Current Pharmaceutical Design, 2007, 13, 1347-1361.	1.9	54
149	AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?. Journal of Antimicrobial Chemotherapy, 2007, 60, 1185-1188.	3.0	70
150	Impact of Three Ampicillin Dosage Regimens on Selection of Ampicillin Resistance in Enterobacteriaceae and Excretion of bla TEM Genes in Swine Feces. Applied and Environmental Microbiology, 2007, 73, 4785-4790.	3.1	84
151	Influence of Inoculum Size on the Selection of Resistant Mutants of Escherichia coli in Relation to Mutant Prevention Concentrations of Marbofloxacin. Antimicrobial Agents and Chemotherapy, 2007, 51, 4163-4166.	3.2	34
152	Spurious urine excretion drug profile in the horse due to bedding contamination and drug recycling: the case of meclofenamic acid. Journal of Veterinary Pharmacology and Therapeutics, 2007, 30, 179-184.	1.3	13
153	Estimation of absolute oral bioavailability of moxidectin in dogs using a semiâ€simultaneous method: influence of lipid coâ€administration. Journal of Veterinary Pharmacology and Therapeutics, 2007, 30, 375-380.	1.3	21
154	Longitudinal Analysis of Gene Expression in Porcine Skeletal Muscle After Post-Injection Local Injury. Pharmaceutical Research, 2007, 24, 1480-1489.	3.5	32
155	Interindividual variability in plasma concentrations after systemic exposure of swine to dietary doxycycline supplied with and without paracetamol: A population pharmacokinetic approach1. Journal of Animal Science, 2006, 84, 3155-3166.	0.5	20
156	Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. European Journal of Pharmaceutical Sciences, 2006, 27, 37-43.	4.0	33
157	The Adrenocorticotropin Stimulation Test: Contribution of a Physiologically Based Model Developed in Horse for Its Interpretation in Different Pathophysiological Situations Encountered in Man. Endocrinology, 2006, 147, 4281-4291.	2.8	22
158	Prion protein in the cerebrospinal fluid of healthy and naturally scrapie-affected sheep. Journal of General Virology, 2006, 87, 3723-3727.	2.9	17
159	Pharmacokinetic and Pharmacodynamic Parameters of Ramipril and Ramiprilat in Healthy Dogs and Dogs with Reduced Glomerular Filtration Rate. Journal of Veterinary Internal Medicine, 2006, 20, 499.	1.6	1
160	Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs. Journal of Veterinary Pharmacology and Therapeutics, 2005, 28, 275-285.	1.3	32
161	A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie. British Journal of Pharmacology, 2005, 144, 386-393.	5.4	34
162	Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. British Journal of Pharmacology, 2005, 146, 642-653.	5.4	79

#	Article	IF	Citations
163	Acute Changes in Muscle Blood Flow and Concomitant Muscle Damage after an Intramuscular Administration. Pharmaceutical Research, 2005, 22, 405-412.	3.5	1
164	Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research, 2005, 66, 700-709.	0.6	45
165	Kinetic studies and production rate of equine (e) FSH in ovariectomized pony mares. Application to the determination of a dosage regimen for eFSH in a superovulation treatment. Journal of Endocrinology, 2004, 182, 43-54.	2.6	17
166	Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint. American Journal of Veterinary Research, 2004, 65, 1533-1541.	0.6	95
167	Alterations of somatotropic function in prion disease in sheep. Journal of Endocrinology, 2004, 183, 427-435.	2.6	9
168	Pharmacokinetics of meloxicam in plasma and urine of horses. American Journal of Veterinary Research, 2004, 65, 1542-1547.	0.6	63
169	Plasma terminal half-life. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 427-439.	1.3	253
170	Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 515-525.	1.3	42
171	Volumes of distribution. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 441-453.	1.3	187
172	Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 455-466.	1.3	239
173	Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 415-425.	1.3	249
174	Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 467-477.	1.3	172
175	Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 265-281.	1.3	36
176	A preclinical pharmacokinetic/pharmacodynamic approach to determine a dose of GnRH, for treatment of ovarian follicular cyst in cattle. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 527-535.	1.3	9
177	Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 479-490.	1.3	238
178	PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 491-502.	1.3	89
179	Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. International Journal for Parasitology, 2004, 34, 1299-1307.	3.1	52
180	Influence of Feeding and Analytical Method on the Bioequivalence of a Racemic Drug Undergoing Enantioselective Enterohepatic Recycling. Journal of Pharmaceutical Sciences, 2004, 93, 590-600.	3.3	4

#	Article	IF	Citations
181	Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. Journal of Veterinary Pharmacology and Therapeutics, 2003, 26, 213-224.	1.3	20
182	Population pharmacokinetics of marbofloxacin in aqueous humor after intravenous administration in dogs. American Journal of Veterinary Research, 2003, 64, 889-893.	0.6	24
183	Influence of sources of dietary vitamin E on the maternal transfer of Î±-tocopherol to fetal and neonatal guinea pigs as determined by a stable isotopic technique. British Journal of Nutrition, 2003, 89, 455-466.	2.3	8
184	A pharmacokinetic model to document the actual disposition of topical ivermectin in cattle. Veterinary Research, 2003, 34, 445-460.	3.0	46
185	Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis-Menten kinetic parameters inin vitrosystems. Xenobiotica, 2002, 32, 895-906.	1.1	8
186	Discriminant value of blood and urinary corticoids for the diagnosis of scrapie in live sheep. Veterinary Record, 2002, 150, 680-684.	0.3	4
187	Intestinal Secretion Is a Major Route for Parent Ivermectin Elimination in the Rat. Drug Metabolism and Disposition, 2002, 30, 626-630.	3.3	102
188	The pharmacokineticâ€“pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 2002, 73, 105-114.	1.9	336
189	Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS PharmSci, 2002, 4, 160-188.	1.3	83
190	Letter to the Editor. Journal of Veterinary Pharmacology and Therapeutics, 2002, 25, 239-239.	1.3	0
191	Free drug fraction vs. free drug concentration: a matter of frequent confusion. Journal of Veterinary Pharmacology and Therapeutics, 2002, 25, 460-463.	1.3	118
192	Plasma Exogenous Creatinine Clearance Test in Dogs: Comparison with Other Methods and Proposed Limited Sampling Strategy. Journal of Veterinary Internal Medicine, 2002, 16, 22.	1.6	42
193	A nonlabeled method to evaluate cortisol production rate by modeling plasma CBG-free cortisol disposition. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E946-E956.	3.5	26
194	Small bowel motility and colonic transit are altered in dogs with moderate renal failure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R230-R238.	1.8	40
195	Use of plasma creatine kinase pharmacokinetics to estimate the amount of exercise-induced muscle damage in Beagles. American Journal of Veterinary Research, 2001, 62, 1375-1380.	0.6	14
196	Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. Journal of Veterinary Pharmacology and Therapeutics, 2001, 24, 35-42.	1.3	45
197	A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. Journal of Veterinary Pharmacology and Therapeutics, 2001, 24, 43-55.	1.3	53
198	Licking behaviour and environmental contamination arising from pour-on ivermectin for cattle. International Journal for Parasitology, 2001, 31, 1687-1692.	3.1	82

#	Article	IF	Citations
199	Overestimation of the predictive value of positives by the usual calculations of the specificity of diagnostic tests. Veterinary Research Communications, 2000, 24, 17-24.	1.6	3
200	Naturally occurring scrapie is associated with a lower CBG binding capacity in ewes. Journal of Endocrinology, 2000, 165, 527-532.	2.6	8
201	Major Hypercorticism Is an Endocrine Feature of Ewes with Naturally Occurring Scrapie. Endocrinology, 2000, 141, 988-994.	2.8	5
202	Comparison of pharmacokinetic profiles of doramectin and ivermectin pour-on formulations in cattle. Veterinary Parasitology, 1999, 81, 47-55.	1.8	84
203	Pharmacokinetic study of 45Ca administered intravenously following intramuscular injection of vitamin D3 or 25-hydroxyvitamin D3 in early weaned lambs. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 1999, 122, 277-282.	1.8	1
204	Measurement of glomerular filtration rate and effective renal plasma flow in the conscious beagle dog by single intravenous bolus of iohexol and p-aminohippuric acid. Journal of Pharmacological and Toxicological Methods, 1999, 41, 17-25.	0.7	50
205	New approaches to detect cortisol administration in the horse. Equine Veterinary Journal, 1999, 31, 278-284.	1.7	7
206	Corticoid Concentrations Are Increased in the Plasma and Urine of Ewes with Naturally Occurring Scrapie. Endocrinology, 1999, 140, 2422-2425.	2.8	4
207	Melatonin and prolactin secretion profile in naturally occurring scrapie in ewe. Journal of Pineal Research, 1998, 24, 117-122.	7.4	2
208	Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. Journal of Veterinary Pharmacology and Therapeutics, 1998, 21, 453-461.	1.3	39
209	Pharmacokinetics of Marbofloxacin in Renal Impairment in the Dog. Veterinary Quarterly, 1998, 20, S104-S104.	6.7	4
210	Cortisol concentrations in post competition horse urine: A French and British survey. Equine Veterinary Journal, 1997, 29, 226-229.	1.7	21
211	In vivo quantification of muscle damage in dogs after general anaesthesia with halothane andpropofol. Journal of Small Animal Practice, 1997, 38, 565-569.	1.2	13
212	Comparative pharmacokinetics of doramectin and ivermectin in cattle. Veterinary Parasitology, 1997, 72, 3-8.	1.8	101
213	A Comprehensive Model for Enrofloxacin to Ciprofloxacin Transformation and Disposition in Dog. Journal of Pharmaceutical Sciences, 1997, 86, 1148-1155.	3.3	53
214	Veterinary drug bioequivalence determination. Journal of Veterinary Pharmacology and Therapeutics, 1997, 20, 79-90.	1.3	25
215	The withdrawal time estimation of veterinary drugs revisited. Journal of Veterinary Pharmacology and Therapeutics, 1997, 20, 380-386.	1.3	37
216	The withdrawal time estimation of veterinary drugs: a nonâ€parametric approach. Journal of Veterinary Pharmacology and Therapeutics, 1997, 20, 374-379.	1.3	30

#	Article	IF	Citations
217	THE EFFECT OF EXPERIMENTAL RENAL FAILURE ON TOLFENAMIC ACID DISPOSITION IN THE DOG. , 1997, 18, 79-91.		21
218	Interspecies variations of corticosteroid-binding globulin parameters. Domestic Animal Endocrinology, 1996, 13, 35-45.	1.6	64
219	Cortisol disposition and production rate in horses during rest and exercise. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1996, 271, R25-R33.	1.8	22
220	In vivo quantification of muscle damage in dogs after intramuscular administration of drugs. British Veterinary Journal, 1995, 151, 189-196.	0.5	23
221	Disposition of creatine kinase activity in dog plasma following intravenous and intramuscular injection of skeletal muscle homogenates. Journal of Veterinary Pharmacology and Therapeutics, 1995, 18, 1-6.	1.3	39
222	A nonâ€invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. Journal of Veterinary Pharmacology and Therapeutics, 1995, 18, 226-235.	1.3	37
223	Non-invasive quantification of organ damage. Comparative Haematology International, 1995, 5, 120-124.	0.5	5
224	Testosterone Administration to Mares: Criteria for Detection of Testosterone Abuse by Analysis of Metabolites in Plasma and Urine. Journal of Analytical Toxicology, 1995, 19, 175-181.	2.8	12
225	Pharmacokinetics and Tissue Uptake of D-Î±-Tocopherol in Sheep Following a Single Intraperitoneal Injection. Journal of Dairy Science, 1995, 78, 1561-1566.	3.4	8
226	Metabolism of tritiated D-Î±-tocopherol and D-Î±-tocopheryl succinate in intraruminally dosed sheep. Journal of Animal Science, 1994, 72, 2124-2130.	0.5	5
227	Quantitative evaluation of an experimental inflammation induced with Freund's Complete Adjuvant in dogs. Journal of Pharmacological and Toxicological Methods, 1994, 32, 63-71.	0.7	19
228	Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. Journal of Veterinary Pharmacology and Therapeutics, 1994, 17, 459-469.	1.3	93
229	Creatine kinase in dog plasma: preanalytical factors of variation, reference values and diagnostic significance. Research in Veterinary Science, 1994, 56, 30-36.	1.9	28
230	Absence of circadian rhythm in the disposition of melatonin in the cow. Journal of Pineal Research, 1993, 15, 141-146.	7.4	5
231	Clinical enzymology for the assessment of organ damage: Interspecific differences. Comparative Haematology International, 1993, 3, 27-32.	0.5	5
232	Creatine kinase in the dog: A review. Veterinary Research Communications, 1993, 17, 353-369.	1.6	82
233	Effect of stage of Ã¦strous cycle on tylosin disposition in genital tract secretions of cows. Research in Veterinary Science, 1993, 54, 32-39.	1.9	5
234	Disposition of prednisolone in the course of subclinical fascioliasis in sheep. Xenobiotica, 1993, 23, 483-493.	1.1	2

#	Article	IF	Citations
235	Pharmacokinetics of a recombinant bovine growth hormone and pituitary bovine growth hormone in lactating dairy cows. Journal of Animal Science, 1993, 71, 1219-1225.	0.5	5
236	Pulsatile secretion of LH in the ram: a re-evaluation using a discrete deconvolution analysis. Journal of Endocrinology, 1992, 133, 75-85.	2.6	7
237	A simple method for the quantitative evaluation of neuromuscular blockade in mice. Journal of Pharmacological and Toxicological Methods, 1992, 27, 129-133.	0.7	6
238	Effect of dietary nitrogen intake on gentamicin disposition in sheep. Journal of Veterinary Pharmacology and Therapeutics, 1992, 15, 416-420.	1.3	7
239	Effect of water deprivation on absorption (oral, intramuscular) and disposition of ampicillin in sheep. Journal of Veterinary Pharmacology and Therapeutics, 1992, 15, 421-432.	1.3	20
240	Effect of Sexual Steroid Hormones on Spiramycin Disposition in Genital Tract Secretions of the Ewe. Journal of Pharmaceutical Sciences, 1992, 81, 33-36.	3.3	1
241	GRF treatment of late pregnant ewes alters maternal and fetal somatotropic axis activity. American Journal of Physiology - Endocrinology and Metabolism, 1991, 260, E575-E580.	3.5	4
242	Spiramycin concentrations in plasma and genitalâ€tract secretions after intravenous administration in the ewe*. Journal of Veterinary Pharmacology and Therapeutics, 1990, 13, 7-14.	1.3	7
243	Comparative benzylpenicillin pharmacokinetics in the dromedary Camelus dromedarius and in sheep. Journal of Veterinary Pharmacology and Therapeutics, 1990, 13, 298-303.	1.3	10
244	Influence of steroid hormone treatments or pregnancy on [3H]prazosin and [3H]rauwolscine binding to myometrial Î±-adrenoceptors in the ewe. Journal of Endocrinology, 1990, 127, 471-479.	2.6	3
245	Circadian profile and production rate of melatonin in the cow. Domestic Animal Endocrinology, 1990, 7, 315-322.	1.6	33
246	Instantaneous Secretion Rate of Growth Hormone in Lambs: Relationships with Sleep, Food Intake, and Posture*. Endocrinology, 1989, 125, 642-651.	2.8	22
247	Comparative incidence of experimental fascioliasis on corticosteroid pharmacokinetics in sheep. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1989, 94, 81-86.	0.2	1
248	Clinical Evaluation of Combined Dexamethasone Suppression/ACTH Stimulation Testing in Dogs with Hyperadrenocorticism, using HPLC for Plasma Cortisol Determination. Transboundary and Emerging Diseases, 1988, 35, 409-416.	0.6	1
249	Kinetic and insecticidal properties of ivermectin residues in the milk of dairy cows. Journal of Veterinary Pharmacology and Therapeutics, 1988, 11, 288-291.	1.3	51
250	Prednisolone Binding to Plasma Proteins in Domestic Species. Journal of Pharmaceutical Sciences, 1988, 77, 937-938.	3.3	13
251	Diurnal and episodic variations of plasma hydrocortisone concentrations in horses. Domestic Animal Endocrinology, 1988, 5, 55-59.	1.6	34
252	In Vivo Pharmacological Characterization of Alpha Adrenergic Receptors in Sheep Myometrium and their Physiological Meaning1. Biology of Reproduction, 1987, 37, 241-248.	2.7	22

#	Article	IF	Citations
253	Fenprostalene in cattle: Evaluation of oxytocic effects in ovariectomized cows and abortion potential in a 100-day pregnant cow. Theriogenology, 1987, 28, 467-480.	2.1	7
254	Secretory profiles and production rate of growth hormone in ruminant lambs. Reproduction, Nutrition, Development, 1987, 27, 525-532.	1.9	6
255	Pharmacokinetics of Methylprednisolone Succinate, Methylprednisolone, and Lidocaine in the Normal Dog and During Hemorrhagic Shock. Journal of Pharmaceutical Sciences, 1987, 76, 528-534.	3.3	10
256	Synovial fluid and plasma kinetics of methylprednisolone and methylprednisolone acetate in horses following intraâ€articular administration of methylprednisolone acetate. Equine Veterinary Journal, 1986, 18, 193-198.	1.7	47
257	Pharmacokinetics of Methylprednisolone, Methylprednisolone Sodium Succinate, and Methylprednisolone Acetate in Dogs. Journal of Pharmaceutical Sciences, 1986, 75, 251-255.	3.3	19
258	Route of administration and uterine response to oxytocin in the ewe. Journal of Veterinary Pharmacology and Therapeutics, 1986, 9, 439-441.	1.3	5
259	Activity of the genital tract and plasma levels of oxytocin and cortisol at the time of mating in the ewe. Journal of Endocrinology, 1985, 105, 323-329.	2.6	15
260	An in vivo model for pharmacokinetic studies in the kidney. Journal of Pharmacological Methods, 1985, 14, 1-11.	0.7	2
261	In vivo and in vitro effects of three glucocorticoids on blood leukocyte chemotaxis in the dog. Veterinary Immunology and Immunopathology, 1985, 10, 245-252.	1.2	10
262	Effect of premedication with acetylpromazine on the disposition kinetics of thiopental. Journal of Veterinary Pharmacology and Therapeutics, 1984, 7, 197-202.	1.3	9
263	Determination of methylprednisolone and methylprednisolone acetate in synovial fluid using high-performance liquid chromatography. Biomedical Applications, 1984, 309, 385-390.	1.7	18
264	Thiopentone pharmacokinetics and electrocorticogram pattern in sheep. Journal of Veterinary Pharmacology and Therapeutics, 1983, 6, 201-209.	1.3	10
265	Nonsteroidal anti-inflammatory agents: Species differences in pharmacodynamics. Veterinary Research Communications, 1983, 7, 359-368.	1.6	9
266	Are Regular Activity Episodes of the Genital Tract Controlled by Pulsatile Releases of Oxytocin?. Biology of Reproduction, 1983, 29, 1183-1188.	2.7	15
267	Pharmacokinetics of oxytetracycline in young cattle: comparison of conventional vs long-acting formulations. American Journal of Veterinary Research, 1983, 44, 1203-9.	0.6	47
268	Spontaneous motility of the cervix in cyclic and ovariectomized ewes and changes induced by exogenous hormones. Reproduction, 1982, 66, 317-326.	2.6	22
269	Dexamethasone Concentrations in Bovine Blood Plasma and Milk After Intravenous Injection. Journal of Dairy Science, 1982, 65, 1921-1924.	3.4	13
270	Electromyographic evaluation of the spontaneous and drug-induced motility of the cervix in sheep. Journal of Pharmacological Methods, 1982, 7, 83-90.	0.7	8

#	Article	IF	Citations
271	Simultaneous Determination of Corticosterone, Hydrocortisone, and Dexamethasone in Dog Plasma Using High Performance Liquid Chromatography. Journal of Pharmaceutical Sciences, 1982, 71, 816-818.	3.3	43
272	The pharmacokinetics of xylazine hydrochloride: an interspecific study. Journal of Veterinary Pharmacology and Therapeutics, 1981, 4, 87-92.	1.3	148
273	Determination of xylazine in plasma using high-performance liquid chromatography. Biomedical Applications, 1981, 222, 308-310.	1.7	12
274	Residue profile of phenylbutazone in the rabbit. A comparative evaluation by tissue kinetics prior to and post mortem. Journal of Veterinary Pharmacology and Therapeutics, 1980, 3, 255-259.	1.3	6
275	Sleep and activity, age and fatness, and the energy expenditure of confined sheep. British Journal of Nutrition, 1977, 38, 445-454.	2.3	38
276	Arousal as a cyclic phenomenon during sleep and hibernation in the Hedgehog (Erinaceus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td	1.2	13
277	Drug Selection and Optimization of Dosage Schedules To Minimize Antimicrobial Resistance. , 0, , 49-71.		21